Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Turpie, A. G.G.
PubMed
Right arrow Articles by Turpie, A. G.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit

Alexander G.G. Turpie*

Hamilton Health Sciences, General Division, 237 Barton Street East, Hamilton, ON, Canada L8L 2X2

* Corresponding author. Tel: +1 905 528 9946; fax: +1 905 521 1551. E-mail address: turpiea{at}mcmaster.ca

Fondaparinux (Arixtra®) is a synthetic selective indirect inhibitor of activated factor X. Administered subcutaneously, the onset of action of fondaparinux is rapid, half of the maximum plasma level being reached within 30 min after injection. Furthermore, the pharmacokinetic and safety profile of fondaparinux allows once-daily subcutaneous administration without any laboratory monitoring, including platelet count. Fondaparinux exhibits a very positive benefit-risk ratio in the prevention of venous thrombo embolism in both surgical and acutely ill medical patients at risk of thrombosis. Its favourable efficacy and safety have also been demonstrated in the initial treatment of symptomatic deep-vein thrombosis and pulmonary embolism, and in patients with non-ST and ST elevation acute coronary syndromes. This review summarizes the data obtained in all phase III clinical trials with fondaparinux in the prevention and treatment of thrombo embolic disorders.

Key Words: Acute coronary syndromes • Anticoagulant • Factor Xa • Fondaparinux • Heparin • Venous thrombo embolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.